Cargando…

Early Presentation of a Rare Complication of Sodium-Glucose Cotransporter-2 Inhibitors 10 Days After Initiation: Case Report and Literature Review

Fournier’s gangrene is an extremely rare infection that can occur in immunocompromised patients, especially those with diabetes. Given the severity of this infection and the new associated link to sodium-glucose cotransporter-2 inhibitors, the US FDA recently issued a warning in August 2018. Few cas...

Descripción completa

Detalles Bibliográficos
Autores principales:	Elshimy, Ghada, Correa, Ricardo, Alsayed, Mahmoud, Jyothinagaram, Sathya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cureus 2019
Materias:	Endocrinology/Diabetes/Metabolism
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6695297/ https://www.ncbi.nlm.nih.gov/pubmed/31423402 http://dx.doi.org/10.7759/cureus.5173

Ejemplares similares

Simple Reason for Hypoglycemia: ACE Inhibitor-induced Severe Recurrent Hypoglycemia in a Nondiabetic Patient
por: Elshimy, Ghada, et al.
Publicado: (2019)

SUN-181 Case Report: Rare Complication of SGLT2 Inhibitors Can Occur Only 10 Days after Starting the Medication
por: Elshimy, Ghada, et al.
Publicado: (2019)

Sudden-onset Hypoglycemia Following Fluid Replacement in a Patient with Dapagliflozin-induced Diabetic Ketoacidosis Without Prior Insulin Use: Case Report
por: Elshimy, Ghada, et al.
Publicado: (2019)

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Benefits Versus Risk
por: Jasleen, Bains, et al.
Publicado: (2023)

Sodium-glucose Cotransporter-2 Inhibitors and Euglycaemic Diabetic Ketoacidosis in the Perioperative Period: Case Report
por: Jhaveri, Urmita, et al.
Publicado: (2019)

A New Hope in Type 2 Diabetes Mellitus Management: Sodium-Glucose Cotransporter 2 Inhibitors
por: Chaurasia, Pallavi Prakash, et al.
Publicado: (2021)

Prolonged Glucosuria With Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Case Report and Review of Literature
por: Aggarwal, Ankita, et al.
Publicado: (2020)

Sodium-Glucose Cotransporter-2 Inhibitor-Induced Euglycemic Diabetic Ketoacidosis Followed by Excessively Low Carbohydrate Diet
por: Tsutsui, Erika, et al.
Publicado: (2021)

Euglycemic Diabetic Ketoacidosis and Sodium-Glucose Cotransporter-2 Inhibitors: A Focused Review of Pathophysiology, Risk Factors, and Triggers
por: Somagutta, Manoj R, et al.
Publicado: (2021)

Comparison of Efficacy and Safety Profile of Sodium-Glucose Cotransporter-2 Inhibitors as Add-On Therapy in Patients With Type 2 Diabetes
por: Hussain, Mazhar, et al.
Publicado: (2021)

Baseline Characteristics Associated With Sodium-Glucose Cotransporter Inhibitor Prescriptions in Type 2 Diabetic Patients in Jazan, Saudi Arabia
por: Somaili, Mohammed, et al.
Publicado: (2022)

Underutilization of Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitors in Diabetic Nephropathy Patients in Government-Run Hospitals in India
por: Maradia, Jay, et al.
Publicado: (2023)

Euglycemic Diabetic Ketoacidosis With Sodium-Glucose Cotransporter-2 Inhibitor Use Post-Bariatric Surgery: A Brief Review of the Literature
por: Iqbal, Qasim Z, et al.
Publicado: (2020)

Type 2 Diabetes Remission and Substantial Body Weight Reduction Achieved with Metformin and a Sodium-Glucose Cotransporter 2 Inhibitor
por: Sugiyama, Seigo, et al.
Publicado: (2020)

Postoperative Euglycemic Ketoacidosis in Type 2 Diabetes Associated with Sodium-Glucose Cotransporter 2 Inhibitor: Insights Into Pathogenesis and Management Strategy
por: Chandrakumar, Harshith P, et al.
Publicado: (2021)

A Literature Review of the Therapeutic Perspectives of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor-Induced Euglycemic Diabetic Ketoacidosis
por: Patel, Khyati, et al.
Publicado: (2022)

A Rare but Life-Threatening Case of Fournier’s Gangrene Caused by Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor, Empagliflozin
por: Jahir, Tahmina, et al.
Publicado: (2022)

Hypomagnesemia-Induced Hypocalcemia Successfully Treated With Sodium-Glucose Cotransport Inhibitor (SGLT-2i), a Case Report
por: Gandhi, Anand, et al.
Publicado: (2021)

Isolated Adrenocorticotropic Hormone Deficiency Secondary to Chronic Opiate Use
por: Raj, Rishi, et al.
Publicado: (2020)

Hypertriglyceridemia-Induced Acute Pancreatitis, Euglycemic Diabetic Ketoacidosis and COVID-19 Infection in a Patient With Type 2 Diabetes Taking a Sodium-Glucose Cotransporter 2 Inhibitor
por: Acevedo-Mendez, Bernardo A, et al.
Publicado: (2021)

A Case of Undiagnosed Functional Gonadotroph Adenoma Leading to Ovarian Hyperstimulation Syndrome
por: Mayur, Omkar, et al.
Publicado: (2022)

The Roles of Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists and Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitors in Decreasing the Occurrence of Adverse Cardiorenal Events in Patients With Type 2 Diabetes
por: Shami, Dalia, et al.
Publicado: (2023)

A Retrospective Study to Examine the Correlation of Bioelectrical Impedance Analysis with Shear-wave Elastography in Indian Patients with Non-alcoholic Fatty Liver Disease and Diabetes on Background Sodium-glucose Cotransporter-2 Inhibitor Therapy
por: Roy, Sayak, et al.
Publicado: (2019)

Insulin enhances renal glucose excretion: relation to insulin sensitivity and sodium-glucose cotransport
por: Ferrannini, Ele, et al.
Publicado: (2020)

Role of Selective Sodium-Glucose Co-Transporter-2 Inhibitors in Managing Cardio-Renal Complications in Type 2 Diabetes Mellitus: Beyond Glycemic Control
por: Onyali, Chike B, et al.
Publicado: (2021)

SAT110 Euglycemic Diabetes Ketoacidosis Associated With Sodium-glucose Cotransporter Inhibitors: A Case Series To Raise Awareness
por: Katwal, Dilasha, et al.
Publicado: (2023)

Effects of Sodium Glucose Cotransporter 2 Inhibitor on Renal Renin-Angiotensin-Aldsoterone System
por: Takeda, Yoshiyu, et al.
Publicado: (2021)

Inflammatory Myofibroblastic Adrenal Tumor: An Extreme Rare Cause of Adrenal Incidentaloma
por: Elshimy, Ghada, et al.
Publicado: (2021)

ODP175 COVID-19 Induced Euglycemic Diabetic Ketoacidosis in a Patient taking Sodium-Glucose Cotransporter-2 Inhibitors
por: Alqaisi, Sura, et al.
Publicado: (2022)

Sodium-glucose cotransporter-2 inhibitors for improving endocrine and metabolic profiles in overweight and obese individuals with polycystic ovary syndrome: a meta-analysis protocol
por: Zhang, Jiaqi, et al.
Publicado: (2022)

THU246 What’s The Importance of GAD Antibodies In Patients With Stiff Person Syndrome
por: Barnett, Anne, et al.
Publicado: (2023)

Sodium-Glucose Linked Transporter Inhibitors as a Cause of Euglycemic Diabetic Ketoacidosis on a Background of Starvation
por: Tauseef, Abubakar, et al.
Publicado: (2020)

Use of Sodium-Glucose Co-Transporter-2 Inhibitors in Type 1 Diabetics: Are the Benefits Worth the Risks?
por: Fatima, Tehreem, et al.
Publicado: (2020)

Differential effect of canagliflozin, a sodium–glucose cotransporter 2 (SGLT2) inhibitor, on slow and fast skeletal muscles from nondiabetic mice
por: Otsuka, Hiroko, et al.
Publicado: (2022)

Renal outcomes with sodium-glucose cotransporters 2 inhibitors
por: Sun, Xiaoya, et al.
Publicado: (2022)

The Cardiovascular Benefits Associated with the Use of Sodium-Glucose Cotransporter 2 Inhibitors – Real-World Data
por: Gallwitz, Baptist
Publicado: (2018)

SUN-188 Contributing Factors Precipitation Diabetic Ketoacidosis in Patients Using Sodium-Glucose Cotransporter-2 Inhibitor
por: Attia, Jonven, et al.
Publicado: (2019)

The Impact of Frequent Glucose Monitoring on the Prevalence of Complications Among Patients With Diabetes in Saudi Arabia
por: Alkhatieb, Maram T, et al.
Publicado: (2023)

MON-910 I’m Not Crazy! I Get a Headache When I Pee: A Case of Metastatic Bladder Paraganglioma
por: Sunny, Sonie, et al.
Publicado: (2020)

SUN-693 What Else Should Be Done in Patients with Uncontrolled Type 2 Diabetes and Severe Insulin Allergy?
por: Elshimy, Ghada, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_dav6lga26c9tj7f0p7idh3ig1u